|
As president and CEO of Cubist Pharmaceuticals, Michael Bonney has overseen the most successful launch of an I.V. antibiotic (Cubicin®) in U.S. history. Prior to assuming his leadership roles at Cubist Mr. Bonney was vice president, sales and marketing for Biogen, Inc. where he built the U.S. commercial organization to launch AVONEX®, an injectable biologic therapy for the treatment of multiple sclerosis. He also served as a member of Biogen's clinical development review board and joint steering committee for the development of natalizumab for treating multiple sclerosis, Crohn's disease, and rheumatoid arthritis. Mr. Bonney's background also includes an extended period of service with Zeneca Pharmaceuticals in various sales and marketing capacities. From 1984 to 1995, he advanced through sales, product management, and sales management positions. He demonstrated his leadership abilities by presiding over a sales group of over 1000 people, and honed his bio-pharmaceutical administrative skills by launching key products, and by overseeing a major two-year process- reengineering program. Mr. Bonney brings experience and expertise to NPS of particular relevance as the company prepares to launch PREOS®, its proprietary drug candidate for the treatment of osteoporosis. | 